Scientific Research Support Component C/Non- Human Primates

猴免疫缺陷病毒(SIV)或猴-人免疫缺陷病毒(SIV)感染恒河猴是HIV-1感染的重要动物模型。非人灵长类(NHP)科学研究支持部分(SRSC)旨在通过提供所有专业知识、基础设施、试剂、人员和动物来支持这一CHAVI-ID，以便在NHP中进行复杂的体内免疫原性和挑战性研究。这个SRSC将包括贝丝以色列女执事医疗中心和耶克斯国家灵长类研究中心(埃默里大学)的领导层，并处于实现CHAVI-ID目标的有利地位。 SRSC的领导将与负责科学焦点#1和#2中描述的研究的研究发现团队密切合作，并积极参与该CHAVI-ID的科学任务。SRSC的主要作用是提供领导和技术专长，以确保在动物选择、研究方案的执行、实验程序、样本采集和分发、免疫学和病毒学研究以及数据收集和分析方面的一致性和质量控制。具体目标是： 1.为支持CHAVI-ID，选择和提供恒河猴，提供特殊的动物护理，用单抗和疫苗进行实验研究，收集免疫学和病毒学测试样本，并进行尸检。这些研究将初步评估： A.HIV-1环境特异性单抗对SIV攻击的保护作用； B.新的艾滋病毒-1环境免疫原和免疫策略的免疫原性和保护效力； 2.通过向合作研究人员提供SIV/SIV感染和未感染的NHP的血液和组织样本来支持CHAVI-ID，以支持基础研究。这些样本将支持焦点1中和抗体的研究，并将有助于阐明焦点2中病毒特异性的CD4+滤泡辅助T细胞(TFH)反应的特征，最初的重点是TFH细胞在疫苗诱导的免疫反应中的发展以及TFH细胞在促进抗体亲和力成熟方面的作用。

Infection of rhesus macaques with simian immunodeficiency virus (SIV) or simian-human immunodeficiency virus (SHIV) is a key animal model for HIV-1 infection. The Nonhuman Primate (NHP) Scientific Research Support Component (SRSC) aims to support this CHAVI-ID by providing all the expertise, infrastructure, reagents, personnel, and animals for the conduct of complex in vivo immunogenicity and challenge studies in NHPs. This SRSC will involve leadership from both Beth Israel Deaconess Medical Center and the Yerkes National Primate Research Center (Emory University) and is well positioned to meet the CHAVI-ID goals. This SRSC leadership will work closely with the research discovery teams responsible for the studies described in Scientific Foci #1 and#2 and participate actively in the scientific mission of this CHAVI-ID. The main role of this SRSC is to provide leadership and technical expertise to ensure consistency and quality control in animal selection, execution of study protocols, experimental procedures, sample acquisition and distribution, immunologic and virologic studies, and data collection and analysis. The Specific Aims are: 1. To support this CHAVI-ID by selecting and providing rhesus macaques, providing exceptional animal care, conducting experimental studies with monoclonal antibodies (MAbs) and vaccines, collecting samples for immunologic and virologic testing, and performing necropsy studies. These studies will initially evaluate: A. Protective efficacy of HIV-1 Env-specific MAbs against SHIV challenge; B. Immunogenicity and protective efficacy of novel HIV-1 Env immunogens and immunization strategies; 2. To support this CHAVI-ID by providing blood and tissue samples from SIV/SHIV-infected and uninfected NHPs to collaborating investigators to underpin basic research studies. These samples will support studies of neutralizing Abs in Focus #1 and will help elucidate the characteristics of virus-specific CD4+ follicular helper T cell (Tfh) responses in Focus #2, with an initial emphasis on the development of Tfh cells during vaccine-induced immune responses and the role of Tfh cells in promoting the affinity maturation of antibodies.